Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL.
Gentile G, Poggio T, Catalano A, Voutilainen M, Lahnalampi M, Andrade-Martinez M, Ma T, Sankowski R, Goncharenko L, Tholen S, Han K, Morgens DW, Prinz M, Lübbert M, Engel S, Hartmann TN, Cario G, Schrappe M, Lenk L, Stanulla M, Duyster J, Bronsert P, Bassik M, Cleary ML, Schilling O, Heinäniemi M, Duque-Afonso J.
Gentile G, et al.
Blood Adv. 2024 Apr 10:bloodadvances.2023011582. doi: 10.1182/bloodadvances.2023011582. Online ahead of print.
Blood Adv. 2024.
PMID: 38598725